J&J Hit with US$110 Million Loss in Talc Cancer-Link Lawsuit

The morning of May 4, 2017, certainly wasn’t good for Johnson & Johnson, which was ordered by a St. Louis jury to pay over US$110 mn to a woman from Virginia who blamed company’s talcum powder for being the root cause of her ovarian cancer. Imerys Talc America, the company which supplies talc to J&J, was also ordered by the court to pay a hefty amount to the woman as punitive damage. Imerys Talc is a part of the Paris-based Imerys SA. The overall verdict is said to be one of the largest jury awards in the U.S. so far in 2017.

J&J Accused of Neglecting People’s Health

There are more than 3,000 lawsuits accusing the healthcare giant of ignoring researches linking its shower to shower and baby talc products to ovarian cancer and failing to give heads up to customers about the potential risk. This defeat has broken the winning streak for Johnson & Johnson, which scored its first talc trial earlier this year and on Tuesday, this month, fended off the first bellwether trial over blood thinner Xarelto.

In other words, it can also be said that this verdict is an addition to the string of losses that happened last year. The sum to be awarded in this verdict has surpassed other losses. In the last year, other Missouri juries came out with verdicts of US$55 million, US$70 million, and US$72 million.

Officials from both J&J and Imerys call this verdict to be a contradiction to the studies of the government and professional scientific organizations who have pegged the talc safe.

“Gray Death” U-47700 that killed Prince Continues to Claim More Lives

Since opioid and related drugs are illegal, how can one be sure of what chemical compound they are buying out on the street and consuming, until repercussions unfold? Among the pills found at the estate of singer and performer Prince, where he was found dead in April 2016, contained U-47700, a category drugs that is rated by the U.S. Drug Enforcement Administration as most dangerous of all.

U-47700 is a lethal opioid combination
Gray death as it is nicknamed, looks like a concrete mix while varying in consistency of chunky and hard material to fine powdered stuff. Gray death is essentially a mixture of a number of opioids that have been linked to four-figure fatal overdoses in the U.S. in the past two decades including heroin, fentanyl, and carfentanil, which is at times used to tranquilize elephants! Users of gray death swallow, inject, snort, or smoke it, although the officials believe that this strong drug with much higher potency than heroin can even put you at risk merely by touching it as it can be absorbed through the skin.

Number of casualties continues to escalate
Prince’s death brought it to the forefront of news stories but gray death has been around for quite some time now, with investigators founding frequent cases in the states of Alabama, Ohio, and Georgia. The Georgia Bureau of Investigation has had nearly 50 gray death overdose cases in the past three years, primarily from Atlanta area. In 2015, Ohio state health officials had to send for CDC scientists to help in escalating number of Fentanyl-related deaths. More than 33,000 people succumbed to opioids related cases in the U.S., with Ohio accounting for the maximum 3,050 drug overdose deaths in 2016.

Predicative Genetic Tests Exhibit Advances in Detecting Disease Risks

San Francisco, California, May 05, 2017: TMR Research discusses the future of the global predictive genetic testing and consumer/wellness in its comprehensive research report. The publication, titled “Predictive Genetic Testing and Consumer/Wellness Genomics Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025,” offers an extensive explanation of the various market drivers responsible for shaping the future of the overall market. The research report states that the growing interest in the study of human gene and the alterations it has gone through over the years has propelled the growth of the global predictive genetic testing and consumer/wellness genomics market.

The growing demand for predictive testing is attributable to the increasing interest in identifying the gene mutations that result in disorders and diseases. The rising pool of people with various types of conditions has also spiked an interest this type of testing as it helps in ascertaining the risk of diseases and their severity. Analysts expect the global market to thrive as effective implementation and usage of predictive testing are expected to change the methods of disease management, thereby giving the healthcare sector an additional boost. Users will be able to gain an insightful assessment of various types of cancer, autism, and heart diseases and their impact on the progeny, thereby allowing preventive care a fair chance.

Growing number of collaborations between big players and research institutes are expected to be the primary growth driver for the global market. The market is also likely to benefit from the plummeting costs of genetic sequencing and introduction of point-solutions in the field of genomics. Rapid technological advancements with integration of cloud solutions and data integration have also been identified as important factors likely to promote the growth of the global market.

The types of tests available in the global predictive genetic testing and consumer/wellness genomics market are predictive testing, consumer genomics and wellness genetics. The predictive testing offers tests such as predictive diagnostics, genetic susceptibility test, and population screening programs. On the other hand, the wellness genetics includes tests such as nutria genetics, metabolism genetics, and skin among others.

Some of the key players operating in the global predictive genetic testing and consumer/wellness genomics market are BGI, 23andMe, Inc, Illumina, Inc, Genesis Genetics, Myriad Genetics, Inc, Pathway Genomics, ARUP Laboratories, and Color Genomics Inc. The research report offers a thorough outlook of the competitive landscape present in the global market along with the assessment of the threat from new entrants and substitutes. The publication also evaluates the research and development strategies of these players, their financial outlook, and their business and marketing plans for the forecast period.

Acne Vulgaris Market Sees Growth with Advent of Novel Therapeutics

San Francisco, California, May 04, 2017: The report, titled “Acne Vulgaris Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025” by TMR Research sheds light on the key developments, market attractiveness, growth drivers, and restraints in the market. The report includes an analysis of the supply chain, apart from a detailed description of the competitive landscape.

One of the most widespread chronic diseases of the sebaceous follicles, acne vulgaris primarily affects the pilosebaceous units in the skin of the face, back, and chest. The skin disorder is characterized by pimples, blackheads or whiteheads, and greasy skin. Due to concerns about their appearance, a number of patients are opting for medical treatments to cure this skin disorder. Combination therapy can treat this condition faster.

Being one of the commonest skin diseases, there are a number of treatments available for acne vulgaris. A wide spectrum of systemic and topical drugs are available in the market, assisting in the advancement of the Acne Vulgaris Market. Some of the most popular therapies recommended for acne vulgaris are combination therapy, topical retinoid, antibiotics, hormonal therapies, and oral isotretinoin. Several dermatologists recommend the use of topical retinoids and benzoyl peroxide. These are available in a variety of formulations such as face washes, gels, creams, and lotions.

High incidence of acne vulgaris, increasing air pollution leading to skin infections, rising awareness about the treatment options available, and the expanding disposable incomes of people are responsible for the steady growth of the global market for acne vulgaris treatments. The recent introduction of advanced drugs such as Galderma’s Epiduo has given an additional impetus to the market. A number of drugs for the treatment of acne vulgaris are in the pipeline. For instance, Photocure’s Visonac, a form of phototherapy, and AndroScience’s ASC-J9 are expected to soon make their appearance in the global market for acne vulgaris. This will further boost the market.

By geography, the global market for acne vulgaris treatments can be segmented into Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. North America presently leads the global scenario, thanks to the growing prevalence of acne vulgaris and high consciousness pertaining to its treatment. Asia Pacific is expected to display growing demand for acne vulgaris treatment, driven by increasing awareness about this skin disease, vast patient base, and rising number of skin infections across the region. China and India are likely to emerge at the fore, representing a substantial share in the regional market for acne vulgaris treatment.

Galderma S.A., Sol-Gel Technologies Ltd., Boehringer Ingelheim GlaxoSmithKline plc, GmbH, Valeant Pharmaceuticals International, Inc., Photocure ASA, Ausio Pharmaceuticals, LLC, Hygeia Therapeutics, and Quest PharmaTech, Inc. are some of the key players in the global market for acne vulgaris.